PHARMACOKINETIC ANALYSIS AND CLINICAL RESULTS OF THE PHASE 1 DOSE ESCALATION AND EXPANSION CXD101 TRIAL IN RELAPSED, REFRACTORY LYMPHOMA
Sign Up to like & getrecommendations! Published in 2017 at "Hematological Oncology"
DOI: 10.1002/hon.2439_186
Abstract: and anemia (12%). The overall response rate (ORR) was 71% (12/17 pts) and median progression‐free survival (PFS) was not estimable across all cohorts; ORR in each subtype was 80% (4/5 pts) in DLBCL with 1… read more here.
Keywords: cll; clinical results; analysis clinical; results phase ... See more keywords
Population pharmacokinetic analysis of rebamipide in healthy Korean subjects with the characterization of atypical complex absorption kinetics
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Pharmacokinetics and Pharmacodynamics"
DOI: 10.1007/s10928-017-9519-z
Abstract: In this study, the population pharmacokinetic (PK) analysis of rebamipide (Reba) in healthy male Korean subjects was analyzed using the nonlinear mixed effects modeling method. The possible effects of physiological covariates and the multidrug resistance… read more here.
Keywords: absorption; reba; population pharmacokinetic; pharmacokinetic analysis ... See more keywords
Population pharmacokinetic analysis of danvatirsen supporting flat dosing switch
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Pharmacokinetics and Pharmacodynamics"
DOI: 10.1007/s10928-019-09619-6
Abstract: Danvatirsen is a Generation 2.5 antisense oligonucleotide under clinical development. Population PK modelling was conducted using data from 3 available danvatirsen Phase I/II studies in oncology patients to investigate the impact of flat dosing on… read more here.
Keywords: flat dosing; analysis; population pharmacokinetic; model ... See more keywords
Simultaneous Pharmacokinetic Analysis of Nitrate and its Reduced Metabolite, Nitrite, Following Ingestion of Inorganic Nitrate in a Mixed Patient Population.
Sign Up to like & getrecommendations! Published in 2020 at "Pharmaceutical research"
DOI: 10.1007/s11095-020-02959-w
Abstract: PURPOSE The pharmacokinetic properties of plasma NO3- and its reduced metabolite, NO2-, have been separately described, but there has been no reported attempt to simultaneously model their pharmacokinetics following NO3- ingestion. This report describes development… read more here.
Keywords: simultaneous pharmacokinetic; model; nitrate; pharmacokinetic analysis ... See more keywords
Population Pharmacokinetic Analysis of Itacitinib, a Selective JAK-1 Inhibitor
Sign Up to like & getrecommendations! Published in 2019 at "Biology of Blood and Marrow Transplantation"
DOI: 10.1016/j.bbmt.2018.12.256
Abstract: Statement of Purpose, Innovation, or Hypothesis Itacitinib is a JAK-1 inhibitor currently in phase III development for the treatment of acute and chronic graft versus host disease (GVHD) in combination with corticosteroids. Itacitinib is primarily… read more here.
Keywords: pharmacokinetic analysis; population; itacitinib; population pharmacokinetic ... See more keywords
Pharmacokinetic analysis of modified‐release metoprolol formulations: An interspecies comparison
Sign Up to like & getrecommendations! Published in 2017 at "European Journal of Pharmaceutical Sciences"
DOI: 10.1016/j.ejps.2016.10.039
Abstract: &NA; In the current study, we investigated the metoprolol absorption kinetics of an in‐house produced oral sustained‐release formulation, matrices manufactured via prilling, and two commercially available formulations, ZOK‐ZID® (reservoir) and Slow‐Lopresor® (matrix) in both New… read more here.
Keywords: absorption; metoprolol; formulation; pharmacokinetic analysis ... See more keywords
Extracorporeal membrane oxygenation may decrease the plasma concentration of remdesivir in a patient with severe coronavirus disease 2019
Sign Up to like & getrecommendations! Published in 2021 at "IDCases"
DOI: 10.1016/j.idcr.2021.e01343
Abstract: Remdesivir is an antiviral drug that results in clinical improvement after five days of treatment and accelerates recovery by 31%. No studies have discussed the pharmacokinetic analysis of remdesivir in patients with severe COVID-19 requiring… read more here.
Keywords: extracorporeal membrane; membrane oxygenation; remdesivir; pharmacokinetic analysis ... See more keywords
Belatacept Pharmacokinetic Analysis of Belatacept Early Steroid Withdrawal Trial (BEST) to Clinical Outcomes and Compared With Reported BENEFIT and BENEFIT‐EXT Pharmacokinetic Analysis
Sign Up to like & getrecommendations! Published in 2025 at "Clinical Transplantation"
DOI: 10.1111/ctr.70172
Abstract: Belatacept (BELA) pharmacokinetic (PK) studies informed dosing strategies used in phase 3 studies, where fixed mg/kg dosing compared a less intensive (LI) and more intensive (MI) regimen. The LI regimen was preferred due to a… read more here.
Keywords: analysis belatacept; early steroid; analysis; pharmacokinetic analysis ... See more keywords
Safety and pharmacokinetic analysis of UGT1A1 genotype-guided dosing of irinotecan.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.3574
Abstract: 3574Background: Irinotecan is commonly used in the treatment of advanced colorectal and pancreatic cancer. The polymorphisms UGT1A1*28 (7 TA repeats) and UGT1A1*93 (SNP -3156G > A) are significantl... read more here.
Keywords: pharmacokinetic analysis; genotype guided; ugt1a1 genotype; safety pharmacokinetic ... See more keywords
Pharmacokinetic analysis of OMO-103 in patient tissues with advanced solid tumors.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.e15168
Abstract: e15168 Background: MYC is a pleiotropic transcription factor aberrantly expressed in up to 70% of human cancers. OMO-103 (Omomyc) is a 91-amino-acids-long polypeptide that derives from the B-HLH-LZ domain of human MYC, containing four amino… read more here.
Keywords: solid tumors; pharmacokinetic analysis; tumor; omo 103 ... See more keywords
Population Pharmacokinetic Analysis of Pazopanib in Patients and Determination of Target AUC
Sign Up to like & getrecommendations! Published in 2021 at "Pharmaceuticals"
DOI: 10.3390/ph14090927
Abstract: Pazopanib is a potent multi-targeted kinase inhibitor approved for the treatment of advanced renal cell carcinoma and soft tissue sarcoma. The pharmacokinetics of pazopanib is characterized by a significant inter- and intra-patient variability and a… read more here.
Keywords: pazopanib; analysis pazopanib; population pharmacokinetic; target ... See more keywords